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A new type of company is offering to scan a person’s genome and reveal the information it holds 
for as little as $1000. Are these services fun novelty items or do they provide valuable information 
that will help people take better care of their health?Last month, the United States Sen-
ate unanimously passed a measure 
expected to encourage Americans 
to take advantage of genetic testing. 
When signed into law, the Genetic 
Information Nondiscrimination Act 
(GINA) will protect individuals against 
health insurance and employment 
discrimination based on their genetic 
information.
The law should ease the concerns of 
many individuals at a time when access 
to genetic information is booming. 
Over 1000 types of genetic tests are 
currently on the market for single-gene 
diseases, like cystic fibrosis and hemo-
philia. And the latest crop of DNA test-
ing services, often sold directly to cus-
tomers, offer to scan a person’s entire 
genome to determine the likelihood of 
developing more common conditions 
like obesity or Alzheimer’s disease.
Whole-genome services, launched in 
the past couple of years, have quickly 
grabbed headlines and people’s imagi-
nations (Figure 1). But beyond 
novelty, the companies market-
ing these products claim that 
knowledge of a person’s genetic 
code will be an important tool 
for making better decisions 
about health and lifestyle, and 
in some cases medical care. 
And in future, the data and tools 
these companies are amass-
ing could provide a resource to 
genetic researchers.
Online Genomes
For 2.5 ml of saliva and US$999, 
23andMe, a genetics startup 
company with headquarters 
in California, delivers genetic 
information on 60 or so condi-
tions—from type II diabetes to 
earwax type. Customers also 
find out about their maternal and pater-
nal ancestry and whether they share 
common ancestors with Ben Franklin 
or U2′s frontman Bono. 23andMe and 
other similar companies—including 
deCODEMe (an offshoot of deCODE 
Pharmaceuticals in Iceland, founded 
by geneticist Kari Stefansson) and Cal-
ifornia-based Navigenics—determine 
the pattern of hundreds of thousands 
of single-nucleotide polymorphisms 
(SNPs) across a person’s genome. 
Because many SNPs are associated 
with disease-causing forms of genes, 
having one SNP versus another signals 
a higher predisposition for developing 
certain conditions.
23andMe tests for over 600,000 
SNPs and makes the results—both the 
raw data and their analysis—available 
to customers through a secure, private 
website. In the Gene Journals section 
of the website customers learn about 
their SNP patterns, or genotypes, and 
their associations with particular traits 
expressed as an odds ratio (that is, the 
odds of someone with that genotype 
developing a trait compared with the 
odds for the general population).
Each association is also given a 
score of 1 to 4 stars depending on the 
validity of the study it was based on. 
“Four stars means that it is a really solid 
study, typically replicated in different 
populations,” says Linda Avey, who 
with Anne Wojcicki (spouse of Google 
cofounder Sergey Brin), founded 
23andMe in 2006. “This field is rapidly 
evolving and we wanted to develop a 
way for our customers to see the pro-
cess as it unfolds. By developing this 
way to categorize research discover-
ies, we hope our customers will come 
to recognize the caveats as well.”
Because so much is still unknown 
about the relationship between SNPs 
and most conditions or the best way to 
calculate risk estimates, the company 
is careful not to oversell its product. 
“We explain that it is not a diagnostic 
test. This is so early in the 
process,” says Avey. “So 
much of the information is 
preliminary. We currently 
show nine SNPs associ-
ated with type II diabetes. 
But there could be ten or 
more genes involved in the 
disease. We don’t have 
the complete picture.”
Getting Ahead of the 
Science?
Only about 5% of diseases 
in developed countries are 
linked to mutations in a spe-
cific gene. The vast majority 
result from a subtle interplay 
among several genes and 
the environment. Scientists 
rely on SNP maps to hone 
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Whole-genome services provide customers with their genetic predisposition 
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in on the multiple genes associated with 
such complex diseases, but interpreting 
the results is a daunting challenge. “There 
might be modifier loci that affect the con-
tribution of different variants. The context 
of the mutation background is important. 
And for every condition, it is always a bal-
ance between nature and nurture. We 
may get a handle on nature but it is very 
difficult to quantify nurture,” says James 
R. Lupski, Cullen professor and vice chair 
of molecular and human genetics and 
professor of pediatrics at Baylor College 
of Medicine. “With genomics we are still 
in the educational stage. Some people 
are having fun with the technology. The 
novelty is there, but the clinical utility is 
currently not.”
Even well-established associa-
tions, such as the ones between cer-
tain SNPs and an individual’s ability 
to metabolize many commonly admin-
istered drugs, provide limited medi-
cal value. “It is good information to 
have. If you are a poor metabolizer you 
should know that,” says Julio Licinio, 
chairman of the department of psy-
chiatry and behavioral sciences at the 
University of Miami Leonard M. Miller 
School of Medicine. “But in terms of 
personal medicine, we don’t know how 
to address this knowledge by adjust-
ing drug dosage. There are no specific 
guidelines.” And whether someone is a 
fast or slow metabolizer becomes irrel-
evant if the person does not respond 
at all to a drug. “The typical result is 
a specific genetic variant increases by 
20% the chance you will respond to 
this drug, but as far as the individual is 
concerned you might not have the vari-
ant and still respond to the drug. So the 
result is not a complete guide to treat-
ment,” says Licinio.
Changing Behavior
Licinio had himself considered sign-
ing up for one of the genome scanning 
services but in the end decided against 
it. “I asked myself is anything going to 
change in my life? I have a history of 
heart disease and cancer in my family, 
so I know I cannot drink a lot of alcohol 
or smoke. I cannot be obese. I have to 
exercise,” he explains. “Will knowing 
that I have a genetic risk factor change 
this? Or if I don’t have a risk factor will 
I just become fat and lazy?”754 Cell 133, May 30, 2008 ©2008 ElsevierYet, companies that provide these 
genome services point out that many 
individuals will benefit from knowing 
their risk factors. “If you have all the 
risk alleles for type II diabetes, it does 
not mean that you will get the disease, 
but you probably should not become 
obese and should monitor certain met-
abolic factors. And you might want to 
start therapy early if you do develop 
the disease,” says genetic researcher 
Dietrich Stephan, who cofounded Nav-
igenics with oncologist David Agus in 
2006. In collaboration with researchers 
at the Mayo Clinic in Rochester, Navi-
genics has begun a study to assess the 
impact of the information it provides to 
individuals—the results of which should 
be available within the year. They hope 
the data will convince skeptics of the 
value of whole-genome testing. “We 
regard genetic information as another 
medical risk factor. If you have two 
copies of the ApoE4 allele your relative 
risk for Alzheimer’s disease increases 
by approximately the same amount as 
being a heavy smoker predisposes you 
to lung cancer,” says Stephan. “It is 
just another tool that doctors can use 
to manage a patient.”
For an initial fee of US$2500, Navi-
genics determines a person’s likeli-
hood for developing about 18 common 
diseases, such as type II diabetes, 
obesity, Alzheimer’s disease, prostate 
cancer, and glaucoma. (The company 
does not screen for ancestry or non-
medical conditions.) A team of genetic 
counselors is available anytime by 
phone to discuss the results. The firm 
also has two in-house physicians who 
help craft the advice given to custom-
ers, including preventive strategies to 
reduce the odds of developing a par-
ticular disease. Clients can pay a yearly 
membership fee of US$250 to continue 
to receive updates and analyses of their 
genomes as more research information 
becomes available.
Pushing the Envelope Further
The genome scans provided by 23andMe 
and Navigenics yield information about 
increased risk for common conditions. 
But SNP technology does not screen for 
disease-causing mutations in specific 
genes, such as the BRCA1 and BRCA2 
genes involved in breast cancer or the  Inc.MSH2, MSH6, and MLH1 genes linked to 
colon cancer. Detecting these so-called 
Mendelian mutations—the presence 
or absence of which are thought to be 
the primary cause of disease—requires 
sequencing the responsible gene. “SNP 
analysis is cheaper but it has limita-
tions,” says Jorge Conde, president 
and CEO of the Massachusetts-based 
company Knome. “Sequencing pro-
vides the most useful platform so that 
is where we started.” In November 2007 
Knome, founded by Harvard geneticist 
George Church, announced the launch 
of the first commercial whole-genome 
sequencing and analysis service for 
individuals.
The Knome service—which comes 
with a US$350,000 pricetag—is more 
hands on than what others provide. A 
team from Knome flies out to meet pro-
spective clients, explains the process, 
and takes blood samples. After sequenc-
ing 98% of a person’s genome—which 
includes an estimated 20,000 genes—
the company analyzes up to 2000 com-
mon and rare conditions. Customers are 
then brought to Cambridge for a round-
table discussion of the findings. “We 
walk through the analysis and conclu-
sions and make sure that the individual 
understands what it all means,” says 
Conde. After the initial consultation the 
company provides ongoing support by 
phone or web. And as the results of new 
research become available, clients will 
be informed of the implications for their 
genome sequence data.
The entire sequencing and analysis 
process currently takes 4 to 6 months. 
As a result, it will initially be offered to 
20 individuals. “This is viewed more as 
a journey and research project rather 
than a product delivered in a box,” says 
Conde. At the moment, the only named 
individuals to have had their complete 
genome sequenced, and whose results 
have been published, are Craig Venter 
and Nobel laureate James Watson.
While genome scanning companies 
typically claim that they do not provide 
diagnoses, genome scans are making 
their way into medical care. Scientists at 
Baylor College of Medicine in Houston 
have developed a “chip” for screening 
Mendelian mutations that lead to condi-
tions that affect people later in life. This 
chip, the first in a series being devel-
oped for different groups of patients, 
can detect over 3000 mutations in 99 
distinct genes involved in diseases such 
as colon cancer, von Hippel Lindau syn-
drome, and a familial form of Parkinson’s 
disease. “This is an inexpensive way to 
screen for common mutations in these 
genes,” says John Belmont, professor 
of molecular and human genetics and 
pediatrics at Baylor. “But we will not get 
100% of mutations.” About half of the 
known Mendelian disease genes carry 
mutations that have been observed in 
more than one family. Taken together, 
these common mutations account for 
between 20% and 99% of mutant alleles 
discovered in those genes.
The array does not screen for SNPs. 
“As medical geneticists we have more 
experience with Mendelian disorders 
and on how to apply this kind of genetic 
information to medical treatment,” says 
Belmont, adding that the chip array is 
only being offered at Baylor to ensure 
that results are followed up with the 
appropriate tests, genetic counseling, 
and medical management delivered by 
Board Certified clinical geneticists and 
genetic counselors. “SNPs give more 
nebulous information,” Belmont points 
out.
Too Many Smoking Guns
As genome scanning services become 
more widely used, some worry that a 
flurry of incidental genomic findings—a 
phenomenon Isaac Kohane at the 
Center of Biomedical Informatics at 
Harvard Medical School refers to as 
the incidentalome—will outweigh any 
potential benefits of the technology.
“If you look at table 3 in the paper 
reporting Jim Watson’s genome, he 
has a number of mutations associated 
with disease. If you are homozygous 
for these alleles, you should have the 
disease, but Watson doesn’t,” says 
Kohane. Part of the reason may be that 
most variants and disease associa-
tions have been found in highly selected 
groups of people. There is little informa-
tion about how prevalent such variants 
are across the general population.
Mutations in the HFE gene, for 
instance, are known to cause hemo-
chromatosis, an iron uptake disorder 
that involves cirrhosis of the liver, dia-
betes, abnormal skin pigmentation, and heart failure. “When a genetic test 
was applied to 41,000 healthy indi-
viduals, 152 were homozygous for the 
known HFE mutation but only one had 
any findings consistent with the dis-
ease. This suggests a huge false posi-
tive rate unless we dramatically reduce 
the prior estimates for the penetrance 
of that mutation,” says Kohane. “Why 
would you want to inflict that anxiety on 
people?”
Kohane was one of the founders and 
is currently a consultant for Corralegen, 
a company that provides genetic tests 
to physicians, and sits on the scientific 
board of Navigenics. Nonetheless, he 
believes that for the moment genetic 
tests are of most value to people who 
have symptoms of a disease, or who 
have a family history or other risk fac-
tors that predispose them to devel-
oping the disease. In such cases, the 
tests can better inform diagnosis and 
treatment. “I guess I am old school,” he 
says. “I don’t think you should do a test 
unless there is a reason.”
Because of the uncertainties of 
genetic information, Kohane and other 
experts feel that it should not be pro-
vided directly to individuals. “I realize 
we are practicing medicine in different 
times. Often I will talk to a family that 
knows more about a disease than I do. 
It may be the first time I am encounter-
ing the disease but they have done a 
thorough Internet search,” says Lupski. 
“But there is still an important aspect 
of clinical interpretation. I would not 
want to just deliver genetic informa-
tion directly to patients without some 
counseling about the limitations of the 
information and the clinical interpreta-
tion of what it may mean for the patient 
and their family.”
A Grand Experiment
Many of the reservations about 
genomic tests have to do with the fact 
that this is a new science. The genomes 
of only two individuals have so far been 
sequenced, and association studies 
using SNPs have been performed in 
relatively small groups of selected indi-
viduals. As a result, the information that 
companies like 23andMe, Navigenics, 
and Knome are obtaining may contrib-
ute to the existing body of knowledge, 
helping to strengthen the science Cellbehind genome scans. The informa-
tion generated by these companies—
whether it is a genome sequence or 
hundreds of thousands of SNPs—be-
longs to the customers and is treated 
as private information. But companies 
expect that some of their customers 
will be willing to share portions of their 
data with researchers. “Right now we 
are providing a service to individu-
als. But over time it might provide an 
opportunity for people studying genet-
ics and genomics to turn to us and our 
clients,” says Conde of Knome.
The surge of genome companies 
many also be providing a push for 
the development of the tools needed 
to interpret genomic data. Steven 
Brenner, a geneticist at the University 
of California, Berkeley, is spearhead-
ing one of many efforts to amalgamate 
SNP and other mutation data in a sin-
gle public database within a framework 
that enables researchers to interpret 
the data. “To get information of value 
you have to read the literature and fig-
ure out associations. It is a huge bur-
den to do this,” says Brenner. “Right 
now this is being done by individual 
companies. But their data is propri-
etary. There is no way of knowing how 
reliable it is, when it should be used, 
for whom it is appropriate.” In conjunc-
tion with Knome, Brenner hopes to 
unveil a prototype “Genome Commons 
Navigator” by this summer at http://
genomecommons.org. “The Navigator 
is a pipeline which takes as input the 
Genome Commons database and an 
individual’s genome or genotype infor-
mation and ultimately yields a report 
of what is genetically distinctive and 
interesting,” he explains.
The rise of genome scanning ser-
vices may trigger change in another 
direction: regulation. “There have 
been calls for increased oversight of 
genetic testing for years, but initially it 
was a small niche market,” says Kathy 
Hudson, director of the Genetics and 
Public Policy Institute in Washing-
ton DC. “People in the business have 
been opposed to enhanced oversight 
because it decreases the ability to 
innovate.” But the growing number of 
genetic tests available and of people 
using these tests are pushing a “broad-
ening consensus among industry labs,  133, May 30, 2008 ©2008 Elsevier Inc. 755
medical communities and consumers 
that there is a need for regulation,” she 
says. Such regulation could take the 
form of enforcement of the U.S. Fed-
eral Trade Commission’s authority to 
prohibit misleading advertising claims 
with respect to genetic tests. It may 
also include a publicly available reg-
istry of companies that offer genetic 756 Cell 133, May 30, 2008 ©2008 Elsevier Intests and oversight of the tests’ accu-
racy and reliability by the U.S. Food 
and Drug Administration.
The possibilities and pitfalls of 
genomic scans will become clear with 
time. But for now 23andMe and other 
companies are forging ahead with 
their vision. “When you branch out into 
something new there is always discus-c.sion about the pros and cons. Right 
now we see more pros in getting the 
information out to people. We are doing 
it in a really responsible way and put-
ting the information in proper context,” 
says Avey of 23andMe. “It is a grand 
experiment but I think we are doing it 
in a way that will benefit people in the 
end.”
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